Dimethyl Fumarate Combined With Vemurafenib Enhances Anti-Melanoma Efficacy via Inhibiting the Hippo/YAP, NRF2-ARE, and AKT/mTOR/ERK Pathways in A375 Melanoma Cells

Melanoma is a deadly form of skin cancer with high rates of resistance to traditional chemotherapy and radiotherapy. BRAF inhibitors (BRAFi) can achieve initial efficacy when used to treat melanoma patients, but drug resistance and relapse are common, emphasizing the need for new therapeutic strateg...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hongxia, Wang, Yaping, Su, Rina, Jia, Yuchen, Lai, Xiong, Su, Huimin, Fan, Yaochun, Wang, Yuewu, Xing, Wanjin, Qin, Jianzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820202/
https://www.ncbi.nlm.nih.gov/pubmed/35141161
http://dx.doi.org/10.3389/fonc.2022.794216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820202/
https://www.ncbi.nlm.nih.gov/pubmed/35141161
http://dx.doi.org/10.3389/fonc.2022.794216

Ejemplares similares